Navigation Links
NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors
Date:3/23/2017

BETHESDA, Md., March 23, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017.

The Company sold to several institutional investors securities totaling 28,843,692 shares, comprised of 18,843,692 common shares at $.26 per share, and 10,000,000 shares of Class C Warrants pre-funded at the closing at $.25 cents per future exercisable shares, with a one cent per share additional payment to be made at the time of actual exercise of these warrants.  This arrangement is to enable investors to avoid exceeding 4.99% ownership while still funding $7.5 million.

Additionally, the investors received five year Class A warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $0.26 per share.  They also will receive three month Class B warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $1.00 per share. 

Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the exclusive placement agent for the transaction.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease."  The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers.  It has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion.  The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks and uncertainties related to the actions and decisions of Nasdaq and Cognate, the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing and expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nw-bio-has-closed-on-its-registered-direct-offering-of-75-million-with-institutional-investors-300428557.html


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Engineered by RoosterBio Inc.: Universal Bioprocess Bags to Streamline Closed System Stem Cell Production
2. Worlds First Robot with Closed System Transfer Device to be Introduced by Equashield to Further Protect Pharmacy Staff During Hazardous Drug Compounding
3. Global Stem Cells Group Subsidiary Adimarket to Launch Progenikine™ SVF Closed System
4. Global Stem Cells Group Announces Manufacturing Phase of Progenikine™ SVF Closed System
5. Global Stem Cells Group in Final Stages of Development of Closed System to Isolate Stem Cells
6. Compact Linear Piezo Nanopositioning Stage Provides 1 Inch Travel, Nanometer Closed-Loop Resolution, Introduced by PI miCos
7. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
8. NW BIO Announces Registered Direct Offering Of $7.5 Million
9. Interpace Diagnostics Announces $4.0 Million Registered Direct Offering of Common Stock
10. BioAmber Inc. announces $7 million underwritten offering of common stock and concurrent $8.9 million registered direct offering of warrants
11. Capricor Therapeutics Announces $4 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2019)... ... ... At the most recent stem cell training course in Las Vegas ... Heroes Program. The Veterans included individuals and families from all over the US, with ... military Veteran, teacher or first responder to receive a regenerative therapy at a training ...
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC ... into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector ... autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related ...
(Date:6/11/2019)... ... June 10, 2019 , ... DeepDyve ... its scientific journals to DeepDyve’s rental service for peer-reviewed journals. , IOPP’s ... of more than 20 million articles, sourced from more than 15,000 journals. , ...
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary forms of ... demand breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen ... engineered T cell receptors known as “CARs”. The CAR enables the final product to ...
Breaking Biology Technology:
(Date:7/21/2019)... , ... July 20, 2019 ... ... Imaging Technologies ( http://www.fluidimaging.com ) announced today the release of the biggest ... particle imaging and characterization platform will provide a significant increase in productivity ...
(Date:7/19/2019)... POWAY, Calif. (PRWEB) , ... July 18, 2019 , ... ... with clinical, regulatory and manufacturing experience. As a result of a two-year ... to commercialize the Calidi oncolytic virus platform in veterinary medicine. VetStem should be ...
(Date:7/19/2019)... ... July 19, 2019 , ... Improved Pharma LLC ... – Insights from Synchrotron X-ray Pair Distribution (SXPDF) Studies”. The authors are Stephen ... of Argonne National Laboratory and Gabriel de Araujo of the University of Sao ...
Breaking Biology News(10 mins):